Pricing coverage on Peptide News Digest tracks list prices, self-pay channels, payer coverage, and the cash economics of compounded peptides.
The highest-traffic moves: Wegovy 4mg oral dose rising from $149 to $199/month effective April 15, 2026 on NovoCare; LillyDirect self-pay tracking; the Foundayo launch tracker via IQVIA showing 5,612 prescriptions in week three; Medicare and CMS rulings on GLP-1 coverage; Hims & Hers and Ro pricing pivots; and the price gap between branded and compounded across telehealth platforms.
For structured drug pricing tables with citations, see the pricing guides. Stories on this tag cover the news around those numbers — price changes, payer wins and losses, and the gap analyses that follow.
Eli Lilly's Foundayo (orforglipron) reached UAE pharmacies on May 12 in Abu Dhabi, expanding from the April Dubai launch. The Emirates Drug Establishment first approved Foundayo on April 3, making the UAE the second country globally to register the once-daily oral GLP-1 pill. Pricing runs from AED 773/month for the 0.8 mg starter dose to AED 1,599/month for the 17.2 mg highest dose. Abu Dhabi has folded Foundayo into the emirate's broader weight-loss program, signaling government coverage rather than purely self-pay. The launch is one of the first international rollouts since FDA approval April 1; Lilly executives have framed UAE prescribing patterns and patient adherence as an early read on geriatric and Middle East regional patient response.
April 20, 2026 is the CMS application deadline for Medicare Part D plans to participate in the BALANCE Model, which will offer Wegovy, Zepbound KwikPen, and Foundayo at $50 copay with a $245/month net price starting July 1. CMS added Foundayo to the Medicare GLP-1 Bridge on April 6 following FDA approval, extending coverage to Lilly's new oral GLP-1.
GoodRx announced oral semaglutide availability via its telemedicine platform at $149 for lower doses, matching Novo Nordisk pricing and intensifying the GLP-1 price war.
Eli Lilly's Foundayo (orforglipron) won FDA approval with aggressive pricing as low as $25/month with savings card. Medicare Part D coverage could bring costs to $50/month starting July 2026.
NBC News covers Foundayo's approval with self-pay pricing from $149-$349/month across six dose tiers. Medicare coverage for some patients could begin as early as summer 2026 with copays as low as $50/month.
Novo Nordisk cut Ozempic prices 36% and Wegovy 48% in India as generic semaglutide from Dr Reddy's, Sun Pharma, and Zydus entered the market with prices as low as Rs 1,290/month.
Pharmacist guide on new self-pay pricing for tirzepatide, navigating insurance and medication switching, with warnings against unsafe compounded GLP-1 products.
Both pharma giants reached most-favored-nation pricing agreements with the Trump Administration to reduce costs of tirzepatide and semaglutide for American consumers.
Novo will reduce prices to $675/month starting January 1, 2027 — approximately 50% cut for Wegovy and 35% for Ozempic, aimed at patients on high-deductible plans.